[{"id":"e17dace3-40cf-43d5-bbae-779980aa63c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02938299","created_at":"2022-04-11T23:53:12.156Z","updated_at":"2024-07-02T16:35:10.976Z","phase":"Phase 3","brief_title":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","source_id_and_acronym":"NCT02938299","lead_sponsor":"Philogen S.p.A.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nidlegy (darleukin/fibromun) • darleukin (L19IL2)"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-08"},{"id":"fb952a87-533f-430a-948a-d2bc777ba023","acronym":"","url":"https://clinicaltrials.gov/study/NCT02076646","created_at":"2021-01-18T09:34:17.257Z","updated_at":"2024-07-02T16:36:12.718Z","phase":"Phase 1/2","brief_title":"A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02076646","lead_sponsor":"Philogen S.p.A.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dacarbazine • darleukin (L19IL2)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 07/31/2013","start_date":" 07/31/2013","primary_txt":" Primary completion: 05/17/2016","primary_completion_date":" 05/17/2016","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-04-14"},{"id":"aa5f72a0-8458-49e8-ae16-a52748f7cb56","acronym":"","url":"https://clinicaltrials.gov/study/NCT02086721","created_at":"2021-01-18T09:37:12.651Z","updated_at":"2025-02-25T16:30:28.148Z","phase":"Phase 1","brief_title":"Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor","source_id_and_acronym":"NCT02086721","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" EGFR • BRAF • ALK • NRAS","pipe":" | ","alterations":" EGFR mutation • BRAF mutation","tags":["EGFR • BRAF • ALK • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e darleukin (L19IL2)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 05/01/2017","primary_completion_date":" 05/01/2017","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2017-05-31"},{"id":"894e5020-753b-422c-8e21-6645b4e724ee","acronym":"ImmunoSABR","url":"https://clinicaltrials.gov/study/NCT02735850","created_at":"2021-01-18T13:23:51.826Z","updated_at":"2025-02-25T16:30:49.817Z","phase":"Phase 2","brief_title":"Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)","source_id_and_acronym":"NCT02735850 - ImmunoSABR","lead_sponsor":"Maastricht Radiation Oncology","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e darleukin (L19IL2)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 02/01/2021","primary_completion_date":" 02/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2017-05-23"}]